When the TRIPS Agreement entered into force in 1995, it was widely read as the high-water mark of intellectual property globalisation. It imposed minimum standards on every WTO member, from twenty-year patent terms to protection for undisclosed test data. Article 1.1 also contained a clause with large consequences: members may implement more extensive protection, provided it does not contravene the Agreement's provisions.

That permission became the foundation of a parallel architecture. Through bilateral and regional agreements, the United States, the European Union and, increasingly, other economies have embedded obligations that exceed TRIPS on nearly every axis, including patent duration, regulatory data, trademarks, copyright and enforcement. These TRIPS-plus provisions now bind a substantial share of the WTO membership, often with fewer of the flexibilities that the multilateral text deliberately preserved for development and public health.

The institutional gap is significant. The 2001 Doha Declaration affirmed that TRIPS should be interpreted and implemented to protect public health and promote access to medicines. Nothing comparable automatically constrains what is negotiated bilaterally, where leverage is asymmetric and IP chapters are traded against market access in agriculture or textiles. Understanding TRIPS-plus requires examining three things together. The first is what the provisions actually require. The second is what the evidence says about their effects on access and innovation. The third is how the negotiating dynamics that produce them can be managed by countries seeking a different balance.

Patent provisions are the most consequential layer. A common feature is patent term adjustment, which compensates rights holders for 'unreasonable' delays in patent examination or marketing approval. In practice it can extend effective protection well beyond twenty years. Many agreements also require patentability of new uses or new forms of known substances. This narrows the space for doctrines such as India's Section 3(d), which the Indian Supreme Court upheld in Novartis v. Union of India (2013) as a legitimate barrier to evergreening.

Regulatory data protection marks the sharpest departure from the multilateral baseline. TRIPS Article 39.3 requires only that undisclosed test data be protected against 'unfair commercial use'. It specifies no period and does not mandate exclusivity. US agreements typically convert this into five years of exclusivity for new chemical entities, during which generic producers cannot rely on the originator's data. Because exclusivity operates independently of patent status, it can block generic entry even for unpatented medicines. Patent linkage reinforces this by making the drug regulator a quasi-enforcement agency for private patent claims.

Several agreements narrow TRIPS flexibilities directly. The US–Jordan FTA restricted the grounds on which compulsory licences could be issued. The US–Australia and US–Morocco agreements permitted patent holders to limit parallel imports through contractual means. Each provision constrains choices that TRIPS Articles 6 and 31 expressly left to national discretion. The legal effect is subtle but important: a measure that would survive a WTO challenge may nonetheless breach a bilateral obligation enforceable through a separate dispute mechanism.

Beyond pharmaceuticals, the inventory extends across the IP system. Copyright terms lengthen from life plus fifty years to life plus seventy. Anti-circumvention rules for technological protection measures often exceed the WIPO Internet Treaties. Mandatory accession to UPOV 1991 constrains traditional seed-saving practices. Trademark chapters protect sound and scent marks and well-known marks irrespective of registration. European agreements, meanwhile, extend geographical indication protection beyond the Article 23 tier for wines and spirits, producing a transatlantic contest over names such as feta and parmesan.

Enforcement provisions complete the architecture. They include ex officio border seizures, pre-established or statutory damages, criminal penalties for commercial-scale infringement, and in some cases border measures on goods in transit. The Anti-Counterfeiting Trade Agreement, rejected by the European Parliament in 2012, was effectively an attempt to codify this enforcement layer plurilaterally outside the WTO. Its collapse did not end the agenda. Much of the same content migrated back into bilateral and regional chapters, where it attracted far less public scrutiny.

Takeaway

TRIPS-plus rarely works through one dramatic obligation. Its force comes from stacking modest-seeming provisions, each of which closes a different exit from exclusivity.

Assessing TRIPS-plus effects is methodologically demanding. Provisions phase in over years and interact with domestic regulatory capacity. They also coincide with unrelated shifts in pricing, procurement and disease burden. Isolating the marginal effect of a data exclusivity clause from everything else happening in a pharmaceutical market is rarely clean. Still, a body of empirical and simulation research has accumulated. Its findings are more consistent than the polarised policy debate would suggest.

The earliest real-world evidence came from Jordan, the first country to accept US-style data exclusivity through its 2000 FTA. Oxfam's 2007 study found that data exclusivity had delayed generic competition for a majority of new medicines launched in the following years, including products with no patent protection in Jordan, which contributed to higher prices. Research on Guatemala under CAFTA-DR, published in Health Affairs in 2009, documented cases with a similar pattern. In those cases regulatory exclusivity, not patents, was the binding barrier to generic entry.

Ex ante impact assessments, many using methodologies developed with the WHO and UNDP, project the fiscal and access consequences of proposed provisions. Studies on Colombia, Thailand and others estimated substantial increases in pharmaceutical expenditure under maximal US demands. These projections carry real uncertainty about prices, substitution and uptake. Their institutional value lies elsewhere: they let governments quantify what they are conceding instead of treating IP chapters as costless bargaining chips.

The innovation counterclaim deserves serious treatment. Kyle and McGahan's analysis of R&D before and after TRIPS found that patent protection in high-income markets was associated with increased pharmaceutical investment. Extending protection to developing countries, however, did not measurably stimulate research into diseases that predominantly affect them. The mechanism is straightforward: exclusivity monetises demand, and demand without purchasing power generates little incentive. This holds however long the protection lasts.

Technology transfer evidence is more nuanced. Branstetter, Fisman and Foley showed that US multinationals increased technology transfer to affiliates, measured through royalty flows and R&D, after host countries strengthened IP regimes. Keith Maskus's work suggests such gains concentrate in middle-income economies with genuine absorptive capacity. For least-developed countries, stronger protection mainly raises the cost of imitation without attracting offsetting licensing. Meanwhile, the technology transfer commitments of developed countries under TRIPS Article 66.2 remain weakly implemented. Uniform TRIPS-plus templates largely ignore this heterogeneity.

Takeaway

The effects of stronger IP depend on the market where it lands. The same provision that encourages licensing in an industrialising economy can simply raise prices in a poorer one.

TRIPS-plus emerged from a strategy that scholars such as Susan Sell and Laurence Helfer describe as forum shifting. Developing countries consolidated an effective coalition at the WTO, culminating in the Doha Declaration. Demandeur states responded by moving their IP ambitions to bilateral venues, where coalitions dissolve and leverage concentrates. The US Special 301 process, with its annual watch lists, supplies continuous unilateral pressure alongside formal negotiations. Thailand discovered this after issuing compulsory licences on HIV and heart medicines in 2006 and 2007.

Within negotiations, IP chapters typically serve as payment for market access in agriculture, textiles or services. Two structural features magnify the cost. First, TRIPS Article 4 requires most-favoured-nation treatment for IP. Concessions granted to one partner therefore generally extend to all WTO members, unlike tariff preferences, which remain discriminatory. Second, commitments operate as a ratchet. Each agreement becomes the baseline for the next, and domestic reversal risks disputes, retaliation or renewed watch-list designation.

Yet TRIPS-plus is not a one-way street. The May 2007 bipartisan agreement in the US Congress softened pharmaceutical provisions in the Peru, Panama and Colombia FTAs. It made patent term adjustment and linkage less rigid and allowed data exclusivity to run concurrently with US approval periods. After the US withdrew from the TPP, CPTPP parties suspended twenty-two provisions, many of them IP obligations, including biologics data protection and copyright term extension. The 2019 USMCA Protocol later removed the ten-year biologics exclusivity entirely.

These episodes point to practical drafting strategies. Negotiators can define pivotal terms narrowly, such as 'new pharmaceutical product' or 'new use', preserving domestic discretion. They can secure concurrent rather than additive exclusivity periods. They can include explicit cross-references to the Doha Declaration and Article 31bis, which entered into force in 2017. Public health safeguards belong in the operative text rather than side letters, whose interpretive weight under the Vienna Convention on the Law of Treaties remains contested.

Institutional preparation matters as much as textual drafting. Independent ex ante impact assessments, coordination among trade, health and IP ministries, and regional coalitions that share negotiating intelligence all reduce information asymmetries. Transition periods tied to development benchmarks rather than fixed dates help. So do review clauses triggered by measurable access outcomes. Together they convert static concessions into adjustable commitments, the kind of calibrated flexibility the multilateral system originally built in through differentiated transition periods.

Takeaway

TRIPS-plus obligations are negotiated outcomes, not natural law. The CPTPP suspensions and the 2007 congressional revisions show the ratchet can turn backwards when evidence and coalitions align.

TRIPS was designed as a floor. Bilateral and regional agreements have steadily raised it without importing the interpretive safeguards attached to the multilateral text. The result is a fragmented landscape in which a country's effective IP obligations depend less on its WTO commitments than on the identity of its trading partners.

The evidence supports calibration rather than wholesale rejection. Stronger protection can facilitate technology transfer where absorptive capacity exists, yet it imposes measurable access costs where it does not. Uniform templates fail precisely because they ignore this variation. The 2022 MC12 decision on COVID-19 vaccine patents showed both the appetite for multilateral recalibration and its limits.

For institutional designers, IP chapters warrant the same rigour as tariff schedules: quantified, sequenced and reviewable. The question is not whether intellectual property deserves protection. It is who decides how much protection, in which forum, and with what mechanisms for correction.